Would you offer imatinib to a patient with a high risk GIST (> 10 cm, low Ki-67, s/p complete resection) who initially declined adjuvant therapy, but is now interested 14 months post surgery?

In general adjuvant treatment is usually initiated within 3 months of diagnosis. It would be helpful to know more detail about this GIST. For example, where was it located, what was the mitotic count and was any mutational analysis performed.

I am not aware of any data which specifically addresses ...